VVOS Vivos Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1716166 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY-28.6%
TTM EPS YoY23.7%
Revenue 3-yr CAGR12.3%
Net income 3-yr CAGR—
Margins
Gross margin60.0%
Operating margin-105.8%
Net margin-107.2%
FCF margin-88.5%
EBITDA margin-96.2%
Returns
ROE-899.5%
ROA-90.7%
ROIC (approx.)-283.8%
Asset turnover0.85x
Leverage & solvency
Liabilities / assets90.5%
Debt / equity0.77x
Current ratio0.22x
Interest coverage-6.03x
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-24.1%
Payout ratio—
Capex / revenue9.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $17.44M | $15.03M |
| Cost of revenue | $6.90M | $6.01M |
| Gross profit | $10.54M | $9.02M |
| R&D expense | $100,000 | $100,000 |
| SG&A expense | $27.73M | $17.88M |
| Operating income | -$19.89M | -$11.17M |
| Interest expense | $1.40M | — |
| Pretax income | -$21.23M | -$11.14M |
| Net income | -$21.17M | -$11.14M |
| EBITDA | -$18.59M | -$10.59M |
| EPS (basic) | -2.07 | -2.22 |
| EPS (diluted) | -2.07 | -2.22 |
| Weighted avg. shares (diluted) | 10.27M | 5.02M |
| Balance sheet | ||
| Cash & equivalents | $2.03M | $6.26M |
| Receivables | $1.58M | $430,000 |
| Current assets | $4.38M | $7.47M |
| PP&E, net | $3.76M | $3.31M |
| Goodwill | $8.57M | $2.84M |
| Intangibles | $4.04M | $409,000 |
| Total assets | $25.15M | $15.28M |
| Current liabilities | $18.08M | $4.98M |
| Short-term debt | $8.35M | — |
| Long-term debt | $469,000 | $1.20M |
| Total debt | $8.82M | $1.20M |
| Total liabilities | $26.70M | $7.33M |
| Shareholders' equity | -$1.49M | $7.95M |
| Net debt | $6.79M | -$5.06M |
| Shares outstanding | 9.29M | 5.89M |
| Cash flow statement | ||
| Operating cash flow | -$15.26M | -$12.69M |
| Capital expenditure | $2.34M | $568,000 |
| Free cash flow | -$17.60M | -$13.26M |
| Investing cash flow | -$7.53M | -$568,000 |
| Financing cash flow | $18.56M | $17.88M |
| Depreciation & amortization | $1.31M | $581,000 |
| Stock-based compensation | $661,000 | $762,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.